MedTrace Logo

Early Detection Initiative for Pancreatic Cancer

NCT04662879 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8869

Last updated 2026-03-12

No results posted yet for this study

Summary

The Early Detection Initiative for Pancreatic Cancer is a multi-center prospective study to determine if algorithm-based screening in patients with glycemically defined new onset hyperglycemia and diabetes has the potential for earlier detection of pancreatic ductal adenocarcinoma.

Conditions

Interventions

OTHER

Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score

ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.

OTHER

Abdominal imaging

Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (\>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.

Sponsors & Collaborators

Principal Investigators

  • Suresh Chari, MD · M.D. Anderson Cancer Center

  • Anirban Maitra, MBBS · M.D. Anderson Cancer Center

  • Bechien Wu, MD · Kaiser Permanente

  • Avinash Kambadakone-Ramesh, MD, FRCR · Massachusetts General Hospital

  • Ziding Feng, PhD · Fred Hutchinson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-14
Primary Completion
2028-01-31
Completion
2028-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04662879 on ClinicalTrials.gov